BRPI0714908B8 - derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende - Google Patents

derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende

Info

Publication number
BRPI0714908B8
BRPI0714908B8 BRPI0714908A BRPI0714908A BRPI0714908B8 BR PI0714908 B8 BRPI0714908 B8 BR PI0714908B8 BR PI0714908 A BRPI0714908 A BR PI0714908A BR PI0714908 A BRPI0714908 A BR PI0714908A BR PI0714908 B8 BRPI0714908 B8 BR PI0714908B8
Authority
BR
Brazil
Prior art keywords
pi3k inhibitor
pharmaceutical composition
proliferative disease
pyrimidine derivatives
agent
Prior art date
Application number
BRPI0714908A
Other languages
English (en)
Inventor
Kawada Hatsuo
Ebiike Hirosato
Ohwada Jun
Morikami Kenji
Koyama Kohei
Hasegawa Masami
Nakamura Mitsuaki
Yoshida Miyuki
Ishii Nobuya
Shimma Nobuo
Yamamoto Shun
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39032956&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0714908(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BRPI0714908A2 publication Critical patent/BRPI0714908A2/pt
Publication of BRPI0714908B1 publication Critical patent/BRPI0714908B1/pt
Publication of BRPI0714908B8 publication Critical patent/BRPI0714908B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

derivado de pirimidina como inibidor de pi3k e uso do mesmo. é fornecido um fármaco que é útil como preventivo ou terapêutico para câncer tendo como resultado efeitos inibidores de pi3k superiores, bem como estabilidade superior no corpo e solubilidade em água. um composto, ou sal farmaceuticamente aceitável deste, representado pela fórmula (i): (i) [em que, x representa, por exemplo, uma ligação simples; y representa, por exemplo, uma ligação simples (contanto que x e y não sejam simultaneamente ligações simples); z representa por exemplo, um átomo de hidrogênio etc.; m representa um número inteiro de 1 ou 2; e r1 representa um substituinte cíclico].
BRPI0714908A 2006-08-08 2007-08-07 derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende BRPI0714908B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2006-216108 2006-08-08
JP2006216108 2006-08-08
JP2007-118631 2007-04-27
JP2007118631 2007-04-27
PCT/JP2007/065396 WO2008018426A1 (fr) 2006-08-08 2007-08-07 Dérivé de pyrimidine comme inhibiteur de la PI3K et son utilisation

Publications (3)

Publication Number Publication Date
BRPI0714908A2 BRPI0714908A2 (pt) 2013-05-28
BRPI0714908B1 BRPI0714908B1 (pt) 2020-10-13
BRPI0714908B8 true BRPI0714908B8 (pt) 2021-05-25

Family

ID=39032956

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0714908A BRPI0714908B8 (pt) 2006-08-08 2007-08-07 derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende

Country Status (26)

Country Link
US (1) US8022205B2 (pt)
EP (1) EP2050749B1 (pt)
JP (1) JP4450857B2 (pt)
KR (1) KR101435692B1 (pt)
AR (1) AR062292A1 (pt)
AU (1) AU2007282535B9 (pt)
BR (1) BRPI0714908B8 (pt)
CA (1) CA2659604C (pt)
CL (1) CL2007002316A1 (pt)
CY (1) CY1119882T1 (pt)
DK (1) DK2050749T3 (pt)
ES (1) ES2657635T3 (pt)
HU (1) HUE035116T2 (pt)
IL (1) IL196601A (pt)
LT (1) LT2050749T (pt)
MX (1) MX2009001451A (pt)
MY (1) MY145385A (pt)
NO (1) NO342978B1 (pt)
NZ (1) NZ575274A (pt)
PE (1) PE20080527A1 (pt)
PL (1) PL2050749T3 (pt)
PT (1) PT2050749T (pt)
RU (1) RU2448109C2 (pt)
SI (1) SI2050749T1 (pt)
TW (1) TWI394758B (pt)
WO (1) WO2008018426A1 (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2125822T3 (en) * 2006-12-21 2015-01-12 Nerviano Medical Sciences Srl SUBSTITUTED PYRAZOLOQUINAZOLINDERIVATER, process for their preparation and their use as kinase inhibitors
CL2009000241A1 (es) * 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
PT2959900T (pt) * 2008-06-16 2017-06-22 Univ Tennessee Res Found Composto para tratamento do cancro
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
WO2010005558A2 (en) * 2008-07-07 2010-01-14 Xcovery, Inc. Pi3k isoform selective inhibitors
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
BRPI0921156A2 (pt) * 2008-11-11 2016-02-23 Xcovery Holding Co Llc inibidores de pi3k/mtor quinase
SG172266A1 (en) 2008-12-19 2011-07-28 Genentech Inc Compounds and methods of use
NZ595372A (en) 2009-03-27 2013-11-29 Vetdc Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2010114494A1 (en) * 2009-04-03 2010-10-07 S*Bio Pte Ltd 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders
RS57869B1 (sr) 2009-06-17 2018-12-31 Vertex Pharma Inhibitori replikacije virusa gripa
AR077280A1 (es) 2009-06-29 2011-08-17 Incyte Corp Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden
EP2451802A1 (en) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
CA2773848A1 (en) * 2009-09-09 2011-03-17 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
MX2012010115A (es) 2010-03-01 2013-02-26 Gtx Inc Compuestos para el tratamiento de cancer.
JP2013529212A (ja) * 2010-05-19 2013-07-18 エクスカバリー ホールディング カンパニー，エルエルシー ｍＴＯＲ選択的キナーゼ阻害剤
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
BR112013020329A2 (pt) * 2011-02-09 2016-08-02 Hoffmann La Roche compostos heterocíclicos como inibidores da pi3-quinase
WO2012135160A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
CA2839937C (en) * 2011-07-05 2020-11-03 Vertex Pharmaceuticals Incorporated Processes and intermediates for producing azaindoles
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
SI2751109T1 (sl) 2011-09-02 2017-03-31 Incyte Holdings Corporation Heterociklilamini kot inhibitorji pi3k
US20130123255A1 (en) * 2011-11-10 2013-05-16 Chugai Seiyaku Kabushiki Kaisha Combination of a pi3k inhibitor and a mek inhibitor
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
JP6381523B2 (ja) 2012-05-16 2018-08-29 ノバルティス アーゲー Ｐｉ−３キナーゼ阻害剤の投与レジメン
CN103450204B (zh) * 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
NO2868660T3 (pt) 2012-07-02 2018-05-26
WO2014022728A1 (en) 2012-08-02 2014-02-06 Endo Pharmaceuticals, Inc Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer
EP2914260A1 (en) 2012-10-31 2015-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
PT2914296T (pt) * 2012-11-01 2018-10-30 Infinity Pharmaceuticals Inc Tratamento de cancros utilizando moduladores de isoformas de pi3-quinase
CN103588792B (zh) 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
JP6139789B2 (ja) 2013-10-16 2017-05-31 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合複素環化合物、その調製方法、医薬組成物及びその使用
SI3068782T1 (sl) 2013-11-13 2018-10-30 Vertex Pharmaceuticals Incorporated Postopki za pripravo inhibitorjev v replikacije virusov gripe
CN111808957A (zh) 2014-04-04 2020-10-23 中美冠科生物技术（太仓）有限公司 用于确定对mek/erk抑制剂的应答性的方法
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
ES2772682T3 (es) 2015-02-27 2020-07-08 Taiho Pharmaceutical Co Ltd Cristal de imidazooxazina, composición farmacéutica que contiene dicho cristal, y método de producción de dicho cristal
CN117800973A (zh) 2015-02-27 2024-04-02 因赛特控股公司 Pi3k抑制剂的盐及其制备方法
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
SG11201809792TA (en) * 2016-05-18 2018-12-28 Piqur Therapeutics Ag Treatment of neurological disorders
WO2018007331A1 (en) 2016-07-08 2018-01-11 F. Hoffmann-La Roche Ag Fused pyrimidine derivatives
JP6980751B2 (ja) 2016-07-14 2021-12-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 縮合ピリミジン誘導体
IT201600092469A1 (it) * 2016-09-14 2018-03-14 Lundbeck Pharmaceuticals Italy S P A Processo per la produzione di Blonanserina
CN109476670B (zh) 2016-10-04 2022-06-28 豪夫迈·罗氏有限公司 二环杂芳基衍生物
MX2019013862A (es) 2017-05-23 2020-01-20 Mei Pharma Inc Terapia de combinacion.
MX2020001727A (es) 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.
US11414420B2 (en) 2017-11-27 2022-08-16 Hoffmann-La Roche Inc. Pyrimidine derivatives
WO2021247862A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Bicyclic heteroarenes and methods of their use
TW202220661A (zh) 2020-08-07 2022-06-01 德商柏林化學股份公司 包含pi3k抑制劑之經改良醫藥調配物
BR112023020806A2 (pt) 2021-04-09 2023-12-12 Immunic Ag Inibidores de dhodh deuterados
WO2023107603A1 (en) * 2021-12-08 2023-06-15 Kineta, Inc. Pyrimidines and methods of their use
WO2023107623A2 (en) * 2021-12-08 2023-06-15 Kineta, Inc. Bicyclic heteroarenes and methods of their use
WO2024023766A1 (en) 2022-07-28 2024-02-01 Berlin-Chemie Ag P13k inhibitor combination therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08325268A (ja) * 1986-02-24 1996-12-10 Mitsui Petrochem Ind Ltd ピロロ〔３，４−ｄ〕ピリミジン誘導体
EP0257102B1 (en) * 1986-02-24 1997-11-19 Mitsui Petrochemical Industries, Ltd. Agents for treating neurophathy
AU645504B2 (en) * 1989-10-11 1994-01-20 Teijin Limited Bicyclic pyrimidine derivative, method of producing the same, and pharmaceutical preparation containing the same as active ingredient
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
CA2426654C (en) 2000-10-23 2010-12-21 Smithkline Beecham Corporation 2,4,8-trisubstituted-8h-pyrido[2,3-d}pyrimidin-7-one compounds
US7384937B2 (en) * 2002-11-06 2008-06-10 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
AU2003295776B2 (en) * 2002-11-21 2011-05-12 Novartis Vaccines And Diagnostics, Inc. 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
EP1622910A1 (en) 2003-05-05 2006-02-08 F. Hoffmann-La Roche Ag Fused pyrimidine derivatives with crf activity

Also Published As

Publication number Publication date
CA2659604A1 (en) 2008-02-14
BRPI0714908A2 (pt) 2013-05-28
CA2659604C (en) 2015-04-28
AU2007282535B9 (en) 2013-06-20
AR062292A1 (es) 2008-10-29
NO20084533L (no) 2009-01-09
IL196601A (en) 2015-03-31
CL2007002316A1 (es) 2008-02-01
WO2008018426A1 (fr) 2008-02-14
KR101435692B1 (ko) 2014-09-01
LT2050749T (lt) 2018-01-10
CY1119882T1 (el) 2018-06-27
AU2007282535A1 (en) 2008-02-14
PL2050749T3 (pl) 2018-03-30
SI2050749T1 (en) 2018-04-30
AU2007282535B2 (en) 2013-05-30
EP2050749B1 (en) 2017-11-22
TWI394758B (zh) 2013-05-01
JPWO2008018426A1 (ja) 2009-12-24
PE20080527A1 (es) 2008-07-09
MY145385A (en) 2012-01-31
DK2050749T3 (en) 2018-01-08
IL196601A0 (en) 2009-11-18
BRPI0714908B1 (pt) 2020-10-13
RU2448109C2 (ru) 2012-04-20
US20100069629A1 (en) 2010-03-18
PT2050749T (pt) 2018-01-02
EP2050749A1 (en) 2009-04-22
EP2050749A4 (en) 2011-03-30
JP4450857B2 (ja) 2010-04-14
ES2657635T3 (es) 2018-03-06
HUE035116T2 (hu) 2018-05-02
NZ575274A (en) 2010-11-26
MX2009001451A (es) 2009-02-18
US8022205B2 (en) 2011-09-20
NO342978B1 (no) 2018-09-17
RU2009108328A (ru) 2010-09-20
TW200817411A (en) 2008-04-16
KR20090047462A (ko) 2009-05-12

Similar Documents

Publication Publication Date Title
BRPI0714908B8 (pt) derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
GT200800256A (es) Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
BRPI0511504A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
BRPI0412343A (pt) derivados de piridazina e seu uso como agentes terapêuticos
BRPI0513184A (pt) derivados de 2-carbamida-4-feniltiazol, preparação dos mesmos e aplicação dos mesmos em terapia
NO20053775L (no) Diazepinoindol derivater som kinaseinhibitorer.
DE60140814D1 (de) N-phenyl-2-pyrimidine-amine derivatives
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
UA97351C2 (ru) Производная кумарина, имеющая противоопухолевую активность
BRPI0606817A2 (pt) derivados de piridazina e seu uso como agentes terapêuticos
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
EA201070588A1 (ru) Производные 1,2,3-триазола для применения в качестве ингибиторов стеароил-соа десатуразы
RU2011138962A (ru) Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
MX2009008386A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pirimidina como inhibidores de proteinas de choque termico-90 para tratar cancer.
AR043662A1 (es) Derivados de guanidina
ECSP099767A (es) Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/08/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF